Loading…
A bill to suspend temporarily the duty on gemifloxacin, gemifloxacin mesylate, and gemifloxacin mesylate sesquihydrate.
Legislative Progress
Introduced
September 6, 2005
Latest Action
September 6, 2005
Primary Sponsor
Edward KennedyDemocratic(MA)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 4,105 other S bills in the 109th — cohort avg 35d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2006 · year_end · Pharmacy
H.R 4944 Miscellaneous Trade and Technical Corrections Act of 2006 regarding tariff and trade issues related to pharmaceuticals H.R.2380, S.1617 and S.3358 regarding Miscellaneous Trade and Technical Corrections Act of 2006
Client expense: Not reported · Firm income: $60,000
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. International Trade Commission (ITC)
2006 · year_end · Taxation/Internal Revenue Code
H.R.4944 Miscellaneous Trade and Technical Corrections Act of 2006 regarding tariff and trade issues related to pharmaceuticals H.R.2380, S.1617 and S.3358 regarding Miscellaneous Trade and Technical Corrections Act of 2006
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. International Trade Commission (ITC)
2006 · year_end · Trade (domestic/foreign)
H.R.4944 Miscellaneous Trade and Technical Corrections Act of 2006 regarding tariff and trade issues related to pharmaceuticals H.R.2380, S.1617 and S.3358 regarding Miscellaneous Trade and Technical Corrections Act of 2006
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. International Trade Commission (ITC)